
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gelaspan
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : Shanghai Zhongshan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Gelaspan vs Crystalloid Therapy in Sepsis
Details : Gelaspan is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Sepsis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2025
Lead Product(s) : Gelaspan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : Shanghai Zhongshan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Expands Heparin Sodium Injection Portfolio To Seven Products
Details : Heparin sodium is an anticoagulant, or "blood thinner," used to prevent and treat blood clots by inhibiting thrombin and other clotting factors via the antithrombin III complex.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2025
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Gains FDA Approval for DUPLEX Delivery of Piperacillin Combo
Details : Piperacillin, a penicillin-class antibacterial, and Tazobactam, a beta-lactamase inhibitor, in the DUPLEX Drug Delivery System and Sodium Chloride, indicated for Intra-abdominal infections.
Product Name : Piperacillin and Tazobactam for Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Piperacillin Sodium,Tazobactam Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Ready-to-Activate Cefazolin 3 Gram Pre-Mix in DUPLEX® Containers
Details : Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.
Product Name : Cefazolin Sodium Injection
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : Cefazolin Sodium,Dextrose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
B. Braun Launches Levetiracetam in Sodium Chloride Injection Portfolio
Details : Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.
Product Name : Levetiracetam-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva® Acquires Critical Cell Therapy Manufacturing Assets From B. Braun
Details : The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.
Product Name : Epidex
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
November 21, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Details : Cefazolin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 25, 2022
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery
Details : Chloroprocaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2019
Lead Product(s) : Chloroprocaine
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Omega-6
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The HOME Study (HPN With OMEGA-3)
Details : Omega-6 is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 14, 2017
Lead Product(s) : Omega-6
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Details : Cefazolin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Surgical Wound Infection.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Cefazolin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
